Company news
Phathom Pharmaceuticals, Inc. news in 2021
Phathom Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
November 11, 2021
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 7, 2021
Phathom Pharmaceuticals Withdraws Public Offering
October 26, 2021
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
October 25, 2021
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 23, 2021
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 20, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 17, 2021
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
September 26, 2021
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 19, 2021
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 7, 2021
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 30, 2021
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 9, 2021
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
August 4, 2021
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 1, 2021
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 24, 2021
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 10, 2021
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
May 5, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 28, 2021
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
April 5, 2021
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
March 29, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 18, 2021